Compare Medpace Holdings Inc (MEDP) vs Quantumscape Corp (QS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs Quantumscape Corp — how do they compare? Medpace Holdings Inc trades at $602 (market cap $16.82B), while Quantumscape Corp trades at $4.67 (market cap $2.82B). The key difference: Medpace Holdings Inc is far larger — about 6× Quantumscape Corp's market cap, and Medpace Holdings Inc is trading nearer its 52-week high, Quantumscape Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Medpace Holdings Inc for 14 Days and Quantumscape Corp for 37 Days on average.
| MEDP | QS | |
|---|---|---|
Market Cap | $16.82B | $2.82B |
Volume | 223,093 | 21,878,246 |
Sector | Health | Consumer Cyclical |
52-Week High | $630.19 | $18.44 |
52-Week Low | $393.42 | $4.52 |
Typical Hold Time | 14 Days | 37 Days |
Enterprise Value | $16.44B | $2.03B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $604.25, up 0.22% today, with a neutral technical signal and strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results expected on October 21, 2026. Revenue grew to $2.53 billion in 2025, with a net income margin of 17.67% and robust ROE of 162.15%. Analyst consensus is a $620.44 price target, though institutional sentiment is mixed with recent CEO share sales.
Outlook remains positive given earnings momentum and projected 2026 revenue growth to $2.8 billion. Key risks include high valuation multiples and insider selling. The stock offers upside to consensus target but requires monitoring of Q3 earnings and competitive pressures in medical services.
QuantumScape (QS) trades at $4.52, down 2.8% today, reflecting ongoing investor skepticism about the solid-state battery developer's commercial timeline. The company remains pre-revenue with negative $435M net income in 2025, though it has beaten EPS estimates in two of the last three quarters. Technical indicators show bearish momentum with the stock trading near key support levels, while analyst sentiment remains cautious with 73% hold ratings.
QS faces significant execution risk with commercialization not expected until 2029, creating substantial uncertainty for investors. The stock trades at a discount to the $10.35 consensus target, offering potential upside if technology milestones are met, but requires high risk tolerance given the lengthy path to profitability and intense competition in battery technology.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About Quantumscape Corp
QuantumScape Corp is engaged in the development of next-generation solid-state lithium-metal batteries for use in electric vehicles. It developed anode-less cell design, which delivers high energy density while lowering material costs and simplifying manufacturing.
Read more on QS →
